JP2004530703A - 結晶形アジスロマイシン - Google Patents

結晶形アジスロマイシン Download PDF

Info

Publication number
JP2004530703A
JP2004530703A JP2002591516A JP2002591516A JP2004530703A JP 2004530703 A JP2004530703 A JP 2004530703A JP 2002591516 A JP2002591516 A JP 2002591516A JP 2002591516 A JP2002591516 A JP 2002591516A JP 2004530703 A JP2004530703 A JP 2004530703A
Authority
JP
Japan
Prior art keywords
azithromycin
ppm
degrees
crystalline
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002591516A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004530703A5 (https=
Inventor
ジェーン リ，ツェン
ビンセント トラスク，アンドリュー
Original Assignee
ファイザー・プロダクツ・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27404135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2004530703(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ファイザー・プロダクツ・インク filed Critical ファイザー・プロダクツ・インク
Publication of JP2004530703A publication Critical patent/JP2004530703A/ja
Publication of JP2004530703A5 publication Critical patent/JP2004530703A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2002591516A 2001-05-22 2002-05-01 結晶形アジスロマイシン Withdrawn JP2004530703A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29256501P 2001-05-22 2001-05-22
US29774101P 2001-06-12 2001-06-12
US34304101P 2001-12-21 2001-12-21
PCT/IB2002/001570 WO2002094843A1 (en) 2001-05-22 2002-05-01 Crystal forms of azithromycin

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2006061758A Division JP4584162B2 (ja) 2001-05-22 2006-03-07 結晶形アジスロマイシン
JP2007030654A Division JP2007161726A (ja) 2001-05-22 2007-02-09 結晶形アジスロマイシン

Publications (2)

Publication Number Publication Date
JP2004530703A true JP2004530703A (ja) 2004-10-07
JP2004530703A5 JP2004530703A5 (https=) 2006-04-27

Family

ID=27404135

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002591516A Withdrawn JP2004530703A (ja) 2001-05-22 2002-05-01 結晶形アジスロマイシン
JP2006061758A Expired - Fee Related JP4584162B2 (ja) 2001-05-22 2006-03-07 結晶形アジスロマイシン
JP2007030654A Pending JP2007161726A (ja) 2001-05-22 2007-02-09 結晶形アジスロマイシン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2006061758A Expired - Fee Related JP4584162B2 (ja) 2001-05-22 2006-03-07 結晶形アジスロマイシン
JP2007030654A Pending JP2007161726A (ja) 2001-05-22 2007-02-09 結晶形アジスロマイシン

Country Status (35)

Country Link
US (10) US6977243B2 (https=)
EP (1) EP1390377B1 (https=)
JP (3) JP2004530703A (https=)
KR (1) KR100574153B1 (https=)
AP (1) AP2003002906A0 (https=)
AR (1) AR036022A1 (https=)
AT (2) ATE404575T1 (https=)
AU (1) AU2002256846B2 (https=)
BG (1) BG108370A (https=)
BR (1) BR0209918A (https=)
CA (1) CA2391659C (https=)
CR (1) CR7159A (https=)
CZ (1) CZ20033154A3 (https=)
DE (2) DE60228345D1 (https=)
DK (1) DK1390377T3 (https=)
EA (2) EA007618B1 (https=)
EE (1) EE200300575A (https=)
ES (2) ES2310886T3 (https=)
GE (1) GEP20084399B (https=)
HU (1) HUP0400446A2 (https=)
IL (1) IL158591A0 (https=)
IS (1) IS7007A (https=)
MA (1) MA27023A1 (https=)
MX (1) MXPA03010028A (https=)
MY (1) MY129319A (https=)
NO (2) NO321894B1 (https=)
NZ (2) NZ539801A (https=)
PA (1) PA8545701A1 (https=)
PE (1) PE20021064A1 (https=)
PL (1) PL367091A1 (https=)
PT (1) PT1390377E (https=)
SK (1) SK14402003A3 (https=)
TN (1) TNSN03121A1 (https=)
WO (1) WO2002094843A1 (https=)
YU (1) YU91603A (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501197A (ja) * 2002-07-22 2006-01-12 プリヴァ−イストラジヴァキ・インスティトゥ・ディー・オー・オー 新規な非晶質９−デオキソ−９ａ−アザ−９ａ−メチル−９ａ−ホモエリスロマイシンＡ、その調製方法、およびその使用
JP2007161726A (ja) * 2001-05-22 2007-06-28 Pfizer Prod Inc 結晶形アジスロマイシン
JP2013163683A (ja) * 2007-08-03 2013-08-22 Cosmo Spa コルテキソロンの１７α−モノエステルおよび／またはその９，１１−デヒドロ誘導体を得るための酵素的方法
US9211295B2 (en) 2001-08-10 2015-12-15 Cassiopea S.P.A. 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents
US10603327B2 (en) 2015-06-22 2020-03-31 Cassiopea S.P.A. High concentration formulation

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
AU768219B2 (en) * 1998-11-30 2003-12-04 Teva Pharmaceutical Industries Ltd. Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof
WO2002015842A2 (en) * 2000-08-23 2002-02-28 Wockhardt Limited Process for preparation of anhydrous azithromycin
KR100431431B1 (ko) * 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
PL371259A1 (pl) * 2001-12-21 2005-06-13 Pfizer Products Inc. Bezpośrednio sprasowywalne preparaty azytromycyny
AU2002353316A1 (en) * 2001-12-21 2003-07-09 Pfizer Products Inc. Methods for wet granulating azithromycin
BR0307331A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Formulações granuladas a seco de azitromicina
CA2422972A1 (en) * 2003-03-21 2004-09-21 Apotex Inc. Isopropanolate of azithromycin and method of manufacturing
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
EP1878432A1 (en) * 2003-07-24 2008-01-16 Pliva - Research and Development Ltd. Single dose fast dissolving azithromycin
EP1648473B1 (en) 2003-07-24 2009-01-28 PLIVA HRVATSKA d.o.o. Single dose fast dissolving azithromycin
CA2678125C (en) * 2003-11-17 2014-10-14 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US20050250714A1 (en) * 2004-05-06 2005-11-10 Lin Kangwen L Crystalline forms of 9-(S)-erythromycylamine
JP2008501657A (ja) * 2004-06-02 2008-01-24 サンド・アクチエンゲゼルシヤフト 結晶形態のメロペネム中間体
US7683162B2 (en) 2004-08-30 2010-03-23 Taro Pharmaceutical Industries Limited Process of preparing a crystalline azithromycin monohydrate
US8495244B2 (en) * 2005-06-29 2013-07-23 Jumpstart Wireless Corporation System and method for dynamic automatic communication path selection, distributed device synchronization and task delegation
US7750153B2 (en) * 2005-07-05 2010-07-06 Hetero Drugs Limited Process for the preparation of didanosine using novel intermediates
EP1904510A1 (en) * 2005-07-14 2008-04-02 Pfizer Products Incorporated Process for forming amorphous azithromycin particles
CN101287706A (zh) * 2005-09-21 2008-10-15 尼科梅德有限责任公司 作为组蛋白脱乙酰基酶抑制剂的磺酰基吡咯盐酸盐
US7728129B2 (en) * 2005-10-31 2010-06-01 Janssen Pharmaceutica Nv Processes for the preparation of piperazinyl and diazapanyl benzamide derivatives
US8558765B2 (en) * 2005-11-07 2013-10-15 Global Oled Technology Llc Method and apparatus for uniformity and brightness correction in an electroluminescent display
AU2007260356B2 (en) * 2006-06-16 2013-01-24 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
NZ598071A (en) * 2006-10-27 2013-08-30 Signal Pharm Llc Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
US7834195B2 (en) * 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
US7919676B2 (en) 2007-08-03 2011-04-05 Pioneer Hi-Bred International, Inc. Msca1 nucleotide sequences impacting plant male fertility and method of using same
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
US8216363B2 (en) * 2008-10-27 2012-07-10 Illinois Institute Of Technology Continuous antisolvent crystallization process and system using plug flow reactors
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
CA2754604A1 (en) 2009-03-13 2010-09-16 Da Volterra Compositions and methods for elimination of gram-negative bacteria
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
PT2544679T (pt) 2010-03-12 2019-07-11 Omeros Corp Inibidores de pde-10 e composições e métodos relacionados
JP2013536859A (ja) * 2010-09-01 2013-09-26 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ｃアゴニストの非吸湿性塩
JP2014530805A (ja) * 2011-09-30 2014-11-20 スンシネ ルアケ プハルマ カンパニー リミテッド アジルサルタンの結晶形並びにその製造及び使用
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
NZ630803A (en) * 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
US9879002B2 (en) 2015-04-24 2018-01-30 Omeros Corporation PDE10 inhibitors and related compositions and methods
US9920045B2 (en) 2015-11-04 2018-03-20 Omeros Corporation Solid state forms of a PDE10 inhibitor
IL326637A (en) * 2017-09-07 2026-04-01 Atnx Spv Llc Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI7910768A8 (en) * 1979-04-02 1996-06-30 Pliva Pharm & Chem Works Process for pripering 11-aza-4-0-cladinosyl-6-0-desosaminyl-15-ethyl- 7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl- oxacyclopentadecane-2-one and their derivatives
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4465674A (en) * 1983-09-06 1984-08-14 Pfizer Inc. Azahomoerythromycin D derivative and intermediates therefor
RO107257B1 (ro) * 1987-07-09 1993-10-30 Pfizer Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
US4983531A (en) * 1990-02-12 1991-01-08 Motorola, Inc. Method of fabricating a single polysilicon bipolar transistor which is compatible with a method of fabricating CMOS transistors
CN1093370A (zh) * 1993-12-10 1994-10-12 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
CN1034734C (zh) 1993-12-10 1997-04-30 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
CA2261732C (en) * 1996-07-29 2001-07-24 Abbott Laboratories Preparation of crystal form ii of clarithromycin
CN1161971A (zh) 1997-01-03 1997-10-15 石家庄制药集团有限公司 一种阿齐霉素结晶及其制备方法
PT102130A (pt) 1998-03-13 1999-09-30 Hovione Sociedade Quimica S A Processo de preparacao de dihidrato de azitromicina
TW546302B (en) * 1998-05-08 2003-08-11 Biochemie Sa Improvements in macrolide production
US6245903B1 (en) * 1998-08-21 2001-06-12 Apotex, Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
AU768219B2 (en) * 1998-11-30 2003-12-04 Teva Pharmaceutical Industries Ltd. Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof
ES2267549T3 (es) * 1999-06-29 2007-03-16 Sandoz Ag Procedimiento para la produccion de azitromicina.
ES2177373B1 (es) 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
CA2396426A1 (en) 2000-01-04 2001-07-12 Teva Pharmaceutical Industries Ltd. Preparation method of azithromycin dihydrate
ES2162764B1 (es) 2000-05-17 2003-04-01 Ercros Ind Sa Forma polimorfica del dihidrato de azitromicina, y su procedimiento deobtencion.
WO2002007736A1 (en) 2000-07-24 2002-01-31 Cadila Pharmaceuticals Limited The process for manufacturing of clear liquid pharmaceutical composition of azithromycin
ES2260047T3 (es) * 2000-07-25 2006-11-01 Laboratorio Silanes, S.A. De C.V. Proceso de etapa unica para la preparacion de 7,16-deoxi-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihidroxi-6-etil-3,5,9,11,13,15-hexametilbiciclo(11.2.1)hexadeca-1(2)-en-ona y obtencion de una forma nueva de 9-deoxo-9a-metil-9a-homoeritromicina a.
ITBO20000471A1 (it) 2000-07-31 2002-01-31 Vieri Ridolfi Dispositivo di supporto per prodotti da fumo particolarmente sigarette .
ES2172417B1 (es) 2000-07-31 2003-09-16 Sint Quimica Sa Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden.
WO2002009640A2 (en) 2000-08-01 2002-02-07 Shiva Prasad Singh Process for the preparation of anhydrous azithromycin
WO2002015842A2 (en) 2000-08-23 2002-02-28 Wockhardt Limited Process for preparation of anhydrous azithromycin
EE05200B1 (et) 2000-11-27 2009-08-17 Biochemie S.A. Asitromtsiin monohdraadina, selle valmistamismeetod ja selle kasutamine ravimkoostises
IN190080B (https=) 2001-01-29 2003-06-07 Alembic Ltd
KR100431431B1 (ko) 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
DK1390377T3 (da) * 2001-05-22 2006-06-19 Pfizer Prod Inc Ny krystalform af azithromycin
EP1446010B1 (en) 2001-10-18 2009-04-15 Teva Pharmaceutical Industries Ltd. Stabilized azithromycin compositions

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007161726A (ja) * 2001-05-22 2007-06-28 Pfizer Prod Inc 結晶形アジスロマイシン
US9895379B2 (en) 2001-08-10 2018-02-20 Cassiopea S.P.A. 17alpha, 21-dihydroxypregnene esters as antiandrogenic agents
US9211295B2 (en) 2001-08-10 2015-12-15 Cassiopea S.P.A. 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents
JP2006501197A (ja) * 2002-07-22 2006-01-12 プリヴァ−イストラジヴァキ・インスティトゥ・ディー・オー・オー 新規な非晶質９−デオキソ−９ａ−アザ−９ａ−メチル−９ａ−ホモエリスロマイシンＡ、その調製方法、およびその使用
US10159682B2 (en) 2007-08-03 2018-12-25 Cassiopea S.P.A. Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
US10716796B2 (en) 2007-08-03 2020-07-21 Cassiopea S.P.A. Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
US9486458B2 (en) 2007-08-03 2016-11-08 Cassiopea Spa Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
JP2016014045A (ja) * 2007-08-03 2016-01-28 カシオペア ソシエタ ペル アチオニ コルテキソロンの１７α−モノエステルおよび／またはその９，１１−デヒドロ誘導体を得るための酵素的方法
JP2013163683A (ja) * 2007-08-03 2013-08-22 Cosmo Spa コルテキソロンの１７α−モノエステルおよび／またはその９，１１−デヒドロ誘導体を得るための酵素的方法
US10166245B2 (en) 2007-08-03 2019-01-01 Cassiopea S.P.A. Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
US12337002B2 (en) 2007-08-03 2025-06-24 Cassiopea S.P.A. Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
US9433628B2 (en) 2007-08-03 2016-09-06 Cassiopea Spa Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives
US11938141B2 (en) 2007-08-03 2024-03-26 Cassiopea S.P.A. Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
US11207332B2 (en) 2007-08-03 2021-12-28 Cassiopea S.P.A. Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives
US11213531B2 (en) 2015-06-22 2022-01-04 Cassiopea S.P.A. High concentration formulation
US11883415B2 (en) 2015-06-22 2024-01-30 Cassiopea S.P.A. High concentration formulation
US10980819B2 (en) 2015-06-22 2021-04-20 Cassiopea S.P.A. High concentration formulation
US10603327B2 (en) 2015-06-22 2020-03-31 Cassiopea S.P.A. High concentration formulation

Also Published As

Publication number Publication date
CR7159A (es) 2004-02-23
NO20035177D0 (no) 2003-11-21
KR100574153B1 (ko) 2006-04-25
BG108370A (bg) 2004-11-30
US6977243B2 (en) 2005-12-20
WO2002094843A1 (en) 2002-11-28
EP1390377A1 (en) 2004-02-25
DE60209704T2 (de) 2006-11-16
CA2391659A1 (en) 2002-11-22
US7053192B2 (en) 2006-05-30
NZ529118A (en) 2005-10-28
DE60209704D1 (de) 2006-05-04
MXPA03010028A (es) 2004-02-12
US7282486B2 (en) 2007-10-16
EA200301115A1 (ru) 2004-04-29
NO321894B1 (no) 2006-07-17
JP2006152002A (ja) 2006-06-15
US20040043944A1 (en) 2004-03-04
AR036022A1 (es) 2004-08-04
ATE404575T1 (de) 2008-08-15
ATE319730T1 (de) 2006-03-15
EE200300575A (et) 2004-04-15
EA007618B1 (ru) 2006-12-29
GEP20084399B (en) 2008-06-10
US20040082527A1 (en) 2004-04-29
HUP0400446A2 (hu) 2004-09-28
NZ539801A (en) 2006-10-27
AU2002256846B2 (en) 2007-04-05
US7105179B2 (en) 2006-09-12
US20050090459A1 (en) 2005-04-28
CA2391659C (en) 2006-05-30
CZ20033154A3 (en) 2004-04-14
ES2310886T3 (es) 2009-01-16
KR20040014525A (ko) 2004-02-14
JP2007161726A (ja) 2007-06-28
PL367091A1 (en) 2005-02-21
AP2003002906A0 (en) 2003-12-31
BR0209918A (pt) 2004-03-30
US7307156B2 (en) 2007-12-11
MA27023A1 (fr) 2004-12-20
EP1390377B1 (en) 2006-03-08
SK14402003A3 (sk) 2004-06-08
US20040043945A1 (en) 2004-03-04
IL158591A0 (en) 2004-05-12
NO20061049L (no) 2003-05-12
IS7007A (is) 2003-10-30
PA8545701A1 (es) 2003-09-05
US20050192234A1 (en) 2005-09-01
PE20021064A1 (es) 2002-11-21
EA200500630A1 (ru) 2006-02-24
MY129319A (en) 2007-03-30
EA009611B1 (ru) 2008-02-28
TNSN03121A1 (en) 2005-12-23
DE60228345D1 (de) 2008-09-25
DK1390377T3 (da) 2006-06-19
US20050256062A1 (en) 2005-11-17
PT1390377E (pt) 2006-06-30
US20030162730A1 (en) 2003-08-28
US20040138149A1 (en) 2004-07-15
US20050245469A1 (en) 2005-11-03
US7309782B2 (en) 2007-12-18
JP4584162B2 (ja) 2010-11-17
ES2258142T3 (es) 2006-08-16
YU91603A (sh) 2006-08-17
US7081525B2 (en) 2006-07-25
US20050256063A1 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
JP4584162B2 (ja) 結晶形アジスロマイシン
AU2002256846A1 (en) Crystal Forms of Azithromycin
JP3897983B2 (ja) マクロライド系抗生物質の新規結晶
CN100354294C (zh) 阿奇霉素的晶形
CA2536501C (en) Crystal forms of azithromycin
EP1671979B1 (en) New Cristal Form of Azithromycin

Legal Events

Date Code Title Description
A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20060206

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20060223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060920

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20061017

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20071003

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20071003

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20071120

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100927